Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$3.86 USD
+0.31 (8.73%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Summit Therapeutics PLC (SMMT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.00 | $8.00 | $8.00 | 125.35% |
Price Target
Only one analyst offered a short-term price target of $8.00 for Summit Therapeutics PLC. This represents an increase of 125.35% from the last closing price of $3.55.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Strong Buy-equivalent recommendation for Summit Therapeutics PLC. This translates to an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 1.00 a month ago based on just one Strong Buy recommendation.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | NA | NA |
Buy | 0 | 0 | 0 | NA | NA |
Hold | 0 | 0 | 0 | NA | NA |
Sell | 0 | 0 | 0 | NA | NA |
Strong Sell | 0 | 0 | 0 | NA | NA |
ABR | 1.00 | 1.00 | 1.00 | NA | NA |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
Not Identified | Not Identified | Not Identified | Not Identified | Not Identified |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 1 |
Average Target Price | $8.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.06 |